In a research note published Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a price target of $5.00, ahead of upcoming pivotal phase III data for vepoloxamer for the treatment of sickle cell disease (SCD) pain crisis.
McCarthy noted, “Pivotal data is approaching this summer. Will it be positive? Based on what we see as the right trial design, the right patients and powering assumptions, we have a positive skew.” Furthermore, “The unmet need in SCD pain crisis and the willingness of SCD patients to partake in the search for a therapy to relieve symptoms, in our view, is evident in the speed of EPIC enrollment and subsequent completion (total of only three years).”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason McCarthy has a yearly average return of -5.9% and a 32.5% success rate. McCarthy has a 39.8% average return when recommending MSTX, and is ranked #3739 out of 4038 analysts.
As of this writing, all the 5 analysts polled by TipRanks rate Mast Therapeutics stock a Buy. With a return potential of 511%, the stock’s consensus target price stands at $2.75.